Immunosuppression at initiation of checkpoint inhibitor therapy
|
Allograft rejection, no./reported cases (%)
|
Tumor responsea, no./reported cases (%)
|
---|
All patientsb
|
15/38 (40)
|
15/32c [47]
|
Single-agent immunosuppressive therapy
|
Prednisone (≤10 mg/day)
|
7/9 (78)
|
5/8 (63)
|
mTOR inhibitors
|
2/3 (67)
|
1/2 (50)
|
Calcineurin inhibitors
|
1/9 (11)
|
2/8 (25)
|
Combination immunosuppressive therapy
|
5/17 (29)
|
7/14 (50)
|
- aDisease remission or stabilization
- bOne patient stopped anti-rejection medication prior to initiation of ipilimumab + nivolumab combination therapy. This patient had allograft rejection after therapy initiation but re-initiated therapy after a 1-week delay and was able to complete induction therapy, achieving partial tumor response
- cIn six patients, the tumor response to checkpoint inhibitor therapy was not evaluated